Stocks to Watch: Great Ajax, Akumin, BioMarin Pharmaceutical

Dow Jones
2023/10/21

By Ben Glickman

 

Great Ajax Corp. said it wouldn't be acquired by Ellington Financial after the two real-estate investment trusts agreed to terminate a previously announced combination. Ellington will pay Great Ajax $5 million in cash and acquire 1.67 million shares of common stock for $6.60 a share in connection with the canceled deal. Shares of Great Ajax sink 17% to $5.29 after-hours.

Akumin said it had reached a deal with private-equity firm Stonepeak to go private, under which Stonepeak would convert its $470 million note to Akumin shares and invest $130 million in the company. The companies said shareholders of Akumin would receive $25 million in cash and some contingent value rights. Shares rise 58% to 23 cents after-hours.

BioMarin Pharmaceutical received approval from the Food and Drug Administration for its Voxzogo treatment in all pediatric age groups. The treatment, which was previously indicated for patients five or older in the U.S., addresses achondroplasia, a growth condition.

 

Write to Ben Glickman at ben.glickman@wsj.com

 

(END) Dow Jones Newswires

October 20, 2023 19:19 ET (23:19 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10